Skip to main content
. 2022 Apr;23(4):1271–1278. doi: 10.31557/APJCP.2022.23.4.1271

Figure 3.

Figure 3

OS in the Chemoradiotherapy Arm. For both (a) OS and (b) PFS, prognosis was good in the high TIL group: OS (70.8% vs. 31.6%, P = 0.012), PFS (63.4% vs. 20.3%, P = 0.001)